Pharma: A setback in a cholesterol drug trial raises concerns about the future of a multibillion-dollar market for cholesterol-lowering treatments.
With Novartis stumbling, Amgen and Eli Lilly are in the spotlight! The pressure’s on as they aim to convert reduced Lp(a) levels into fewer heart attacks and strokes. Who will lead the way in this critical health challenge? 🫀💪 #HeartHealth #PharmaRace
What's Your Reaction?
Like
0
Dislike
0
Love
0
Funny
0
Angry
0
Sad
0
Wow
0
